The report below details early stage (angel – Series A) healthcare financings in October 2014 using the data captured by CB Insights. It analyzes the following about early stage healthcare financings:
- Overall financing trends
- Investments by US region
- Mean & median deal sizes
- The month’s largest deals
- The most active VCs
OCTOBER EARLY-STAGE HEALTHCARE FUNDING DOWN YoY
Early-stage healthcare deals and dollars both fell slightly versus the previous month, while funding was down 26% versus the same month a year prior.
EAST COAST REMAINS DOMINANT
Eastern US healthcare companies garnered the bulk of early-stage deals, accounting for 47% in October, with healthcare hub Massachusetts leading the way.
SILICON VALLEY DOLLAR SHARE SKYROCKETS
Early-stage tech funding share to Silicon Valley healthcare companies jumped drastically in October 2014 versus the same month a year prior, behind Imago Biosciences’ $26.5M Series A.
EARLY-STAGE HEALTHCARE DEAL SIZE REACHES TWO-YEAR HIGH
October set a new two-year high for median deal size at $5.03M. This was the second straight month of growth as September’s median total was 80% higher than the previous month’s.
HEALTHCARE ANGEL DEAL SIZE REMAINS RANGE BOUND
Angel deal sizes in healthcare have remained relatively range bound since June.
SEED DEAL SIZES REACH TWO-YEAR HIGH
Both median and average healthcare seed rounds reached two-year highs in October, behind UK-based Magnus Life Science’s $25M super-sized financing. No other seed deals in healthcare in October were greater than $10M.
SERIES A ROUNDS DOWN YoY IN OCTOBER
After an average Series A peak in December 2013 due to Juno Therapeutics’ $120M financing, average healthcare rounds are down 25% YoY in October, and 7% on a median basis.
MEDICAL DEVICES FALL TO LOWEST DEAL SHARE IN TWO YEARS
Medical devices accounted for just 15% of all early-stage healthcare deals in October 2014, its lowest share of the past two years. The contribution of other life science categories (disease diagnosis, drug manufacturing, etc.) accounted for 31% of all early-stage healthcare deals, a two-year high, highlighting the diversity of companies being funded within the healthcare space.
BIOTECH FUNDING SHARE RETURNS TO NORMAL
After September saw Adaptimmune raise $104M and push biotech to a 73% funding share, October fell back down to 38% as biotech and medical devices accounted for over 50% of early-stage healthcare dollars for the 4th straight month.
SERIES A DOMINATES DEAL SHARE
Series A rounds accounted for 69% of all early-stage healthcare investments in October, higher than any month in the past two years. Angel investment share fell for the third straight month, and was down from 16% in October 2013.
TOP 10 DEALS CUMULATIVELY RAISE $188M
Four early-stage companies raised rounds of $20M+ in October including Imago Biosciences who raised a $26.5M led by Clarus Ventures. Also of note, four of the top ten deals were in international companies including Magnus Life Science, Highland Therapeutics, Levicept, and Forendo Pharma.
|2||Magnus Life Science||Medical Devices & Equipment||25.0|
|2||Highland Therapeutics||Drug Delivery||25.0|
|4||Raze Therapeutics||Drug Discovery||24.0|
|7||Forendo Pharma||Drug Development||15.2|
|8||Paragon Bioservices||Medical Facilities & Services||13.0|
|8||Zynerba Pharmaceuticals||Drug Development||13.0|
NOVARTIS VENTURE FUNDS & ATLAS ARE MOST ACTIVE
Few VCs made multiple early-stage healthcare investments in October, but Novartis Venture Funds and Atlas Venture both were among the most active, with 3+ investments each.
|1||Novartis Venture Funds|
|2||Dolby Family Ventures|
For more information around early-stage healthcare financings, login to CB Insights’ venture capital database or sign up for free below.
This report was created with data from CB Insights’ emerging technology insights platform, which offers clarity into emerging tech and new business strategies through tools like:
- Earnings Transcripts Search Engine & Analytics to get an information edge on competitors’ and incumbents’ strategies
- Patent Analytics to see where innovation is happening next
- Company Mosaic Scores to evaluate startup health, based on our National Science Foundation-backed algorithm
- Business Relationships to quickly see a company’s competitors, partners, and more
- Market Sizing Tools to visualize market growth and spot the next big opportunity